−0.95EUR
−16.96 MEUR
9.47 MEUR
17.29 M
About NEWRON PHARMACEUTICALS S.P.A.
Sector
CEO
Stefan Weber
Headquarters
Bresso
Website
Founded
1999
ISIN
IT0004147952
FIGI
BBG002K2RNH0
Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of NP5 is 6.90 EUR — it has decreased by 6.76% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on XETR exchange NEWRON PHARMACEUTICALS S.P.A. stocks are traded under the ticker NP5.
NEWRON PHARMACEUTICALS S.P.A. is going to release the next earnings report on Sep 19, 2024. Keep track of upcoming events with our Earnings Calendar.
NP5 stock is 7.25% volatile and has beta coefficient of 0.59. Check out the list of the most volatile stocks — is NEWRON PHARMACEUTICALS S.P.A. there?
One year price forecast for NEWRON PHARMACEUTICALS S.P.A. has a max estimate of 14.10 EUR and a min estimate of 14.10 EUR.
NEWRON PHARMACEUTICALS S.P.A. revenue for the last quarter amounts to 2.23 M EUR despite the estimated figure of 2.71 M EUR. In the next quarter revenue is expected to reach 3.50 M EUR.
Yes, you can track NEWRON PHARMACEUTICALS S.P.A. financials in yearly and quarterly reports right on TradingView.
NP5 stock has fallen by 11.20% compared to the previous week, the month change is a 12.66% fall, over the last year NEWRON PHARMACEUTICALS S.P.A. has showed a 47.44% increase.
NP5 net income for the last quarter is −9.56 M EUR, while the quarter before that showed −7.01 M EUR of net income which accounts for −36.28% change. Track more NEWRON PHARMACEUTICALS S.P.A. financial stats to get the full picture.
Today NEWRON PHARMACEUTICALS S.P.A. has the market capitalization of 138.85 M, it has decreased by 5.46% over the last week.
No, NP5 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NP5 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEWRON PHARMACEUTICALS S.P.A. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEWRON PHARMACEUTICALS S.P.A. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEWRON PHARMACEUTICALS S.P.A. stock shows the buy signal. See more of NEWRON PHARMACEUTICALS S.P.A. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NEWRON PHARMACEUTICALS S.P.A. future price: according to them, NP5 price has a max estimate of 14.10 EUR and a min estimate of 14.10 EUR. Read a more detailed NEWRON PHARMACEUTICALS S.P.A. forecast: see what analysts think of NEWRON PHARMACEUTICALS S.P.A. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NEWRON PHARMACEUTICALS S.P.A. EBITDA is −11.90 M EUR, and current EBITDA margin is −126.18%. See more stats in NEWRON PHARMACEUTICALS S.P.A. financial statements.